Redesigned Clinically Low-Risk Report

Oncotype DX Genomic Prostate Score Assay

Introducing the newly re-designed Oncotype DX GPS assay report for clinically low-risk prostate cancer patients.

20-Year Outcomes: Adverse Pathology

Oncotype DX Genomic Prostate Score Assay

New follow-up data suggests adverse pathology as a predictor of prostate cancer specific mortality and metastasis for clinically low-risk prostate cancer patients for up to 20 years after diagnosis.

2021 SABCS® Meeting

December 7-10, 2021

Visit us at 2021 SABCS® to learn more about how the Oncotype test portfolio can help guide treatment decisions for your breast cancer patients.

Symposium at the 22nd Annual Scientific Meeting in Urologic Oncology

December 1, 2021, 12-1pm ET - Orlando, Florida

Join Dr. Edward Uchio at SUO 2021 to learn more about how the Oncotype test portfolio can help guide treatment decisions for your localized to advanced prostate cancer patients.
Making cancer care smarter.™